ACADIA Pharmaceuticals Inc. (ACAD) Stock Score, Valuation & Financial Research
ACADIA Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 68/100.
Quick answer for ACAD
ACADIA Pharmaceuticals Inc. currently has a Wall Street Score of 68/100. The stored market price is $27.83. Its financial score is 40/100. Its valuation score is 97/100. The latest WSS change is +2.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What ACADIA Pharmaceuticals Inc. does
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP
ACAD financial snapshot
- Wall Street Score:
- 68/100
- Current price:
- $27.83
- Market capitalization:
- $4.77B
- Revenue:
- $1.14B
- Net income:
- $380.5M
- Free cash flow:
- $105.1M
- Cash:
- $385.0M
- Total debt:
- $73.9M
- EPS:
- 2.25
- P/E ratio:
- 12.4x
- Financial score:
- 40/100
- Valuation score:
- 97/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $105.1M, showing positive cash generation.
- The balance sheet shows $385.0M of cash versus $73.9M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +2.4 points: ACAD increased 2.4 points because Valuation improved by 14.6 points.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ACAD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.